EVIDENCE FROM FATAL COVID-19 FOR TARGETING THE BRADYKININ METABOLISM-A SINGLE-CENTER COHORT STUDY.
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
29
12
2023
pubmed:
25
10
2023
entrez:
25
10
2023
Statut:
ppublish
Résumé
Background: Severe progression of COVID-19 to critical illness, with pulmonary failure, multiple organ failure, and death, is driven by systemic inflammatory responses with overproduction of inflammatory cytokines. In the past years, the potential role of bradykinin, leading to inappropriate immune responses in the pathogenesis of COVID-19, has been raised in a so-called bradykinin storm. However, clinical investigations of bradykinin, its metabolite des-Arg 9 -bradykinin, or substance P, are rare or completely lacking during intensive care of COVID-19 patients. A prospective prolonged cohort study was conducted, including 44 COVID-19 patients (09/2020-02/2021, prevalent wildtype SARS-CoV-2) from the intensive care unit. Plasma levels of bradykinin, des-Arg 9 -bradykinin, and substance P were measured daily by ELISA in survivors (n = 21) and nonsurvivors (n = 23) of COVID-19 from admission until discharge or death. Results: We found significantly higher plasma levels of des-Arg 9 -bradykinin in survivors and nonsurvivors of COVID-19 compared with healthy controls. In addition, plasma des-Arg 9 -bradykinin levels were higher ( P < 0.001, effect size = 0.79) in nonsurvivors compared with survivors of COVID-19 and correlated significantly with disease worsening, and clinical parameters of inflammation, like leukocyte count, IL-6 or lactate dehydrogenase, and outcome. Consequently, compared with healthy controls, bradykinin and substance P plasma levels were significantly reduced in survivors and nonsurvivors of COVID-19. Furthermore, plasma substance P levels were significantly reduced ( P < 0.001, effect size = 0.7) in nonsurvivors compared with survivors of COVID-19, whereas plasma bradykinin levels did not significantly differ between survivors and nonsurvivors of COVID-19. Conclusion: Our data demonstrates that des-Arg 9 -bradykinin is significantly elevated in COVID-19 intensive care unit patients and is associated with disease severity, clinical inflammatory parameters, and survival. These results indicate that des-Arg 9 -bradykinin, not bradykinin, is one of the pivotal peptides of concern for the lethal COVID-19 aggravation and outcome. Further investigations are necessary to evaluate whether des-Arg 9 -bradykinin exhibits potent blood biomarker properties in COVID-19 and offer new treatment approaches.
Identifiants
pubmed: 37878473
doi: 10.1097/SHK.0000000000002231
pii: 00024382-202312000-00001
doi:
Substances chimiques
Bradykinin
S8TIM42R2W
Receptors, Bradykinin
0
Substance P
33507-63-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
727-738Informations de copyright
Copyright © 2023 by the Shock Society.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
WHO Coronavirus (COVID-19) Dashboard. WHO coronavirus (COVID-19) dashboard with vaccination data. July 2023.
He J, Lin Y, Cai W, et al. Efficacy of supplemental hemoadsorption therapy on severe and critical patients with COVID-19: an evidence-based analysis. Shock . 2023;60:333–344.
Horby P, Lim WS, Emberson JR, et alRECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med . 2021;384:693–704.
Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N Engl J Med . 2021;384:20–30.
Cavaillon J-M, Artigas A, Barratt-Due A, et al. Severe coronavirus disease 2019: from pathogenesis to therapy. Shock . 2023;59:10–15.
Domingo P, Mur I, Pomar V, et al. The four horsemen of a viral apocalypse: the pathogenesis of SARS-CoV-2 infection (COVID-19). EBioMedicine . 2020;58:102887.
Retamozo S, Brito-Zerón P, Sisó-Almirall A, et al. Haemophagocytic syndrome and COVID-19. Clin Rheumatol . 2021;40:1233–1244.
Garvin MR, Alvarez C, Miller JI, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife . 2020;9:e59177.
Roche JA, Roche R. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. FASEB J . 2020;34:7265–7269.
van de Veerdonk FL, Netea MG, van Deuren M, et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife . 2020;9:e57555.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell . 2020;181:271–280.e8.
Karamyan VT. Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19? Physiol Rep . 2021;9:e14796.
Cohen J: Statistical Power Analysis for the Behavioral Sciences. Hoboken: Taylor and Francis, 2013.
Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis . 2020;20:e192–e197.
Pons MJ, Ymaña B, Mayanga-Herrera A, et al. Cytokine profiles associated with worse prognosis in a hospitalized Peruvian COVID-19 cohort. Front Immunol . 2021;12:700921.
Sunkara H, Dewan SMR. Coronavirus disease-2019: a review on the disease exacerbation via cytokine storm and concurrent management. Int Immunopharmacol . 2021;99:108049.
Wilczynski SA, Wenceslau CF, McCarthy CG, et al. A cytokine/bradykinin storm comparison: what is the relationship between hypertension and COVID-19? Am J Hypertens . 2021;34:304–306.
Aysert-Yildiz P, Ozger HS, Yildiz Y, et al. Prognostic value of serial measurement of serum des-Arg(9)-bradykinin levels in severe COVID-19 patients. Clin Lab . 2022;68(7). doi:10.7754/Clin.Lab.2021.211110.
doi: 10.7754/Clin.Lab.2021.211110
Alfaro E, Díaz-García E, García-Tovar S, et al. Impaired kallikrein-kinin system in COVID-19 patients' severity. Front Immunol . 2022;13:909342.
Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem . 2002;277:14838–14843.
Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol . 2018;314:L17–L31.
Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun . 2020;11:1620.
Mortaz E, Jamaati H, Roofchayee ND, et al. Decreased serum levels of angiotensin converting enzyme (ACE)2 and enhanced cytokine levels with severity of COVID-19: normalisation upon disease recovery. Heliyon . 2022;8:e08957.
Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis . 2008;51:613–623.
Pagliaro P, Penna C. ACE/ACE2 ratio: a key also in 2019 coronavirus disease (COVID-19)? Front Med (Lausanne) . 2020;7:335.
Wakahara S, Konoshita T, Mizuno S, et al. Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinology . 2007;148:2453–2457.
Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature . 2005;436:112–116.
Leeb-Lundberg LMF, Marceau F, Müller-Esterl W, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev . 2005;57:27–77.
Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci . 2005;99:6–38.
Cyr M, Lepage Y, Blais C Jr., et al. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol . 2001;281:H275–H283.
Kuoppala A, Lindstedt KA, Saarinen J, et al. Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am J Physiol Heart Circ Physiol . 2000;278:H1069–H1074.
Saameli K, Eskes TK. Bradykinin and cardiovascular system: estimation of half-life. Am J Physiol . 1962;203:261–265.
Vanarsa K, Henderson J, Soomro S, et al. Upregulation of proinflammatory bradykinin peptides in systemic lupus erythematosus and rheumatoid arthritis. J Immunol . 2020;205:369–376.
Qin L, Du Y, Ding H, et al. Bradykinin 1 receptor blockade subdues systemic autoimmunity, renal inflammation, and blood pressure in murine lupus nephritis. Arthritis Res Ther . 2019;21:12.
Marceau F, Regoli D. Therapeutic options in inflammatory bowel disease: experimental evidence of a beneficial effect of kinin B1 receptor blockade. Br J Pharmacol . 2008;154:1163–1165.
Göbel K, Pankratz S, Schneider-Hohendorf T, et al. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. J Autoimmun . 2011;36:106–114.
Bastian S, Loillier B, Paquet JL, et al. Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization. Br J Pharmacol . 1997;122:393–399.
Jones C, Phillips E, Davis C, et al. Molecular characterisation of cloned bradykinin B1 receptors from rat and human. Eur J Pharmacol . 1999;374:423–433.
Hess JF, Borkowski JA, Macneil T, et al. Differential pharmacology of cloned human and mouse B2 bradykinin receptors. Mol Pharmacol . 1994;45:1–8.
Cabrini DA, Calixto JB. Characterization of des-Arg9-bradykinin-induced contraction in guinea-pig gallbladder in vitro. Eur J Pharmacol . 1997;331:31–38.
Al-Shamlan F, El-Hashim AZ. Bradykinin sensitizes the cough reflex via a B2 receptor dependent activation of TRPV1 and TRPA1 channels through metabolites of cyclooxygenase and 12-lipoxygenase. Respir Res . 2019;20:110.
Ravichandran R, Mohan SK, Sukumaran SK, et al. An open label randomized clinical trial of indomethacin for mild and moderate hospitalised COVID-19 patients. Sci Rep . 2022;12:6413.
Hirata R, Nabe T, Kohno S. Augmentation of spontaneous cough by enalapril through up-regulation of bradykinin B1 receptors in guinea pigs. Eur J Pharmacol . 2003;474:255–260.
Qadri F, Bader M. Kinin B1 receptors as a therapeutic target for inflammation. Expert Opin Ther Targets . 2018;22:31–44.
R Core Team. R: A Language and Enviroment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: https://www.R-project.org/ . Accessed December 4, 2023.
Russell V. Lenth. emmeans: Estimated Marginal Means, aka Least-Squares Means. R package version 1.8.8.;2021. Available at: https://CRAN.R-project.org/package=emmeans . Accessed December 4, 2023.
Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics . 2011;12:77.
Kolde R. pheatmap: Pretty Heatmaps. R package version 1.0.12. Available at: https://CRAN.R-project.org/package=pheatmap . Accessed December 4, 2023.